FDA Cardiotoxicity Group Paper To Suggest Use Of Troponins As Biomarkers
Executive Summary
FDA's cardiotoxicity biomarker working group is preparing a position paper recommending the use of cardiac troponins as a biomarker of cardiac injury
You may also be interested in...
FDA Vascular Injury Group To Study Three Drugs For Predictive Biomarkers
An FDA expert working group has selected three drugs to use to identify biomarkers predictive of drug-induced vasculitis in nonclinical drug safety programs
FDA Vascular Injury Group To Study Three Drugs For Predictive Biomarkers
An FDA expert working group has selected three drugs to use to identify biomarkers predictive of drug-induced vasculitis in nonclinical drug safety programs
Cardiac safety biomarkers
Biomarkers of cardiac and drug-induced injury will be discussed by the FDA Pharmaceutical Science Advisory Committee/Nonclinical Studies Subcommittee Sept. 9-10. The subcommittee will consider reports from its expert working groups: the cardiotoxicity biomarker working group is preparing a position paper recommending the use of cardiac troponins as a biomarker of cardiac injury (1"The Pink Sheet" Nov. 19, 2001, p. 8). Potential transfer of oversight of the subcommittee to the National Center for Toxicological Research's Science Advisory Board will also be revisited at the meeting. The meeting will be at 5630 Fishers Lane, Rockville, Md., at 1:30 p.m. on Sept. 9 and 8 a.m. on Sept. 10...